

ProtoKinetix, Inc.

Stock Symbol: [PKTX](#)

Corporate Website: www.ProtoKinetix.com



PATENTED ANTI-INFLAMMATION TECHNOLOGY POISES PKTX FOR GROWTH

ProtoKinetix, Inc. ([PKTX.OB](#)) is a biotech company based out of Vancouver, British Columbia that has developed and patented a unique family of Glycopeptide molecules (AAGP™). The Company joins professionals in the fields of cell biology, military medicine, healthcare and research. PKTX has developed revolutionary skincare and medical solutions for various applications in the stem cell, cosmetic and healthcare markets. ProtoKinetix is in dialogue with some major pharmaceutical companies to partner the development of this non toxic and effective therapeutic.

AAGP™ is a synthetic form of AFGP (Anti Freeze Glycoprotein) which is derived from certain plants, insects and water dwelling fish/animals that enable survival at extremely cold temperatures. Dr. Geraldine Castelot Deliencourt invented AAGP™ through scientific research and biotechnology. Cells are essential to life functions and are vital to the health of tissues and organs that are subjected to damage caused by aging, disease and stress. Clinical tests have shown AAGP™'s ability to protect, repair and extend the life of cells, organs and tissues. Key focus is treatments that reverse damage by oxidation that cause diseases and debilitating conditions.

Inflammation is the cause of a vast number of human diseases. The current treatment options are extremely limited and often carry very severe side effects. Evidence, over the last four years has been rapidly building to demonstrate the exceptionally powerful anti inflammation effect of AAGP™ molecules. Every single cell line treated with AAGP™, regardless of the hostile antagonists used to trigger inflammation, have consistently proven resistant to inflammation.

To fast track the non steroidal anti inflammatory drug development, PKTX has been focusing on the application of topical therapies for acute diseases such as Iritis (inflammation of the eye) and Dermatitis (inflammation of the skin). There are 2 mechanisms of action in an anti inflammatory. First, AAGP™ acts as a cytostatic agent, slowing down and stopping the metabolism of the cells. Lastly, the end result is a complete elimination of the inflammation.

In 2004 PKTX filed for their first patent which was granted by INSA in 2006. In October 2011, the Company received a master patent by France's Institute for Applied Science for successful testing in 6 treatment areas. Clinical tests were performed in the U.S. and Europe researching AAGP™'s safety and effectiveness for protecting cells, repairing cell damage and lengthening a cell's life span.

NEWS And UPDATES

Oct 24, 2011: French Patent office issued PKTX the master patent on the AAGP™ family of molecules. The proprietary molecules were successfully tested to be stable and non toxic in the treatment of inflammation and aging; organ transplantation and cell, tissue, blood and cryopreservation.

Marketability increases with the patent giving PKTX the ability to commercialize cell technology with major corporations and research facilities.

Sept 21, 2011: Dr. Gregory Evans, Ophthalmology Professor, had success in eye inflammation treatment studies. AAGP™ penetrates the eye and treats inflammation without side effects. The AAGP™ cell technology is a major advancement that treats the eye without corticosteroids that can damage sight – [Read News Release](#)

INVESTORS SUMMARY

Stock Symbol: [PKTX.OB](#)

Share Price: \$0.03

Market Cap: \$3.02 Million

Shares Outstanding:
94.46 Million

[AAGP Presentation](#)



November 2011

Page 2



ProtoKinetix, Inc.

Stock Symbol: [PKTX](#)

Corporate Website:
www.ProtoKinetix.com

ProtoKinetix Technology

- Invented by Dr. Geraldine Castelot Deliencourt
- Patent protected with INSA (France's Institute of Applied Sciences)

AAGP™ Micro Molecules

- Clinical Test Results
- Safe
- No Toxicity
- High Stability
 - Survives extreme temperatures, radiation, oxidation & starvation
 - Remains unchanged with high acidity or alkaline concentrations
- Anti-Inflammatory
- Anti-Oxidant
 - Protects cells from oxidation/environmental stress
 - Preserves cells, tissues and organs
 - Lengthen life span of blood platelets and components
 - Co Enzyme Q10 joined with AAGP™ strengthens repair effect
- High Absorption
 - Minute size (580 Daltons) penetrate cells for repair and protection
- Highly Soluble
 - Fat, alcohol and water solubility

President/CEO:
Ross L. Senior

Executive Offices:
2225 Folkstone Way
West Vancouver, BC
V7S 2Y6 Canada

Phone: (604) 926-6627

Fax: (604) 926-6632

e-mail:
info@protokinetix.com

www.ProtoKinetix.com

Media and Investor Relations

Princeton Research, Inc.
3887 Pacific St,
Las Vegas, Nevada 89121

Phone: (702) 650-3000

mike@princetonresearch.com

Contact: Mike King

www.PrincetonResearch.com

Target Markets

Commercial Applications

Healthcare Solutions

- Cell, tissue and organ harvesting, storage and transplantation
- Treatment of diseases and debilitating conditions caused by stress that causes inflammation, oxidation and radiation leading to tissue damage

Cosmetic Applications

- Protect skin cells from damage and death caused by aging and UV exposure
- Reformulated with existing skincare products or Coenzyme Q10 gives skin a more youthful, radiant and firmer appearance.

Stem Cells

- Shown to relieve symptoms of Parkinson's, Alzheimer's, Diabetes and Multiple Sclerosis
- Testing shows repair effects on cells and tissues from injured organs, limbs or the spinal cord

Prepared by Gina La Cavera and Mike King of Princeton Research, Inc. (<http://www.princetonresearch.com>) Rule 17B: requires disclosure of monies paid for investor relations. Princeton Research and assigns were paid 1,000,000 shares of PKTX 144 restricted stock to do investor relations work. This newsletter may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. We use words such as "expects", "anticipates", "believes", "estimates", the negative of these terms and similar expressions to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.